KNSA.NASDAQKiniksa Pharmaceuticals International, PLC

Form 4: Kiniksa Pharmaceuticals Executive Ross Moat Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Kiniksa Pharmaceuticals International, PLC
🔒Login to Follow

Ross Moat, Chief Commercial Officer of Kiniksa Pharmaceuticals, reports the vesting of restricted share units and subsequent tax withholding.

Summary

  • On April 1, 2024, Ross Moat, the Chief Commercial Officer of Kiniksa Pharmaceuticals, had 1,612 Class A Common Shares acquired through the vesting of Restricted Share Units (RSUs).
  • Also on April 1, 2024, 880 Class A Common Shares were disposed of at a price of $19.70 for tax withholding purposes.
  • Following these transactions, Moat directly owns 15,152 Class A Common Shares and 4,833 Restricted Share Units.
  • The RSUs vest over a four-year period, with 25% vesting annually starting April 1, 2023.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard executive compensation practices; therefore, the sentiment is neutral.

Industry Context

This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, common among publicly traded companies. It provides transparency into the transactions of company insiders.

Stakeholder Impact

  • The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.

Key Dates

DateDescription
04/01/2023Grant date for the Restricted Share Units (RSUs), with 25% vesting annually over four years.
04/01/2024Date of transaction: vesting of 1,612 Restricted Share Units and disposal of 880 Class A Common Shares for tax withholding.
04/03/2024Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.